Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Circulating tumor cell (CTC) levels have clearly been shown to have relevance to the prognosis of men with metastatic, castration-resistant prostate cancer, but we still know little about their potential importance in men with early stage disease.
Filed under: Management, Risk | Tagged: circulating tumor cells, CTC, radical prostatectomy | 11 Comments »
When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.”
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agonist, antagonist, GnRH, LHRH | 2 Comments »
Dan Zenka and the Prostate Cancer Foundation have set up two online petitions asking the National Football League (NFL) to “step up” and support the cause for prostate cancer.
Filed under: Uncategorized | 8 Comments »
According to a report yesterday in Consumer Affairs, “American men with prostate cancer were 45 percent less likely to die from the disease in 2006 than they were in 1999.”
Filed under: Living with Prostate Cancer | Tagged: decline, PCSM, prostate cancer-specific mortality | 10 Comments »
Ketoconazole has long been used as a “third-line” agent in men with castration-resistant prostate cancer (CRPC) who have progressive disease after standard forms of hormonal therapy. For some patients, ketoconazole can be clinically effective and cost-effective compared to other clinical options.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acid, acid-suppressive, castration-resistant, CRPC, ketoconazole, suppression | 5 Comments »
A common topic of discussion among some members of the patient and patient advocacy community is whether recommended management of prostate cancer for individual patients is driven by the potential revenue available to physicians and hospitals from differing recommendations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, low risk, Management, revenue, Treatment | 7 Comments »
Historically, “success” in the treatment of localized prostate cancer was the elimination of all evidence of cancer from the patient’s prostate and other nearby tissues — through radical surgery or radiation therapy of some type. But the increasing acceptance of active surveillance and the evolution of focal forms of therapy have introduced whole new ways [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, control, cure, focal therapy, risk | 4 Comments »
Over the years there have been almost no publications addressing the complications of proton beam radiation therapy (PBRT) among well-defined series of prostate cancer patients. With the number of PBRT centers now growing fast, good data on the side effects of PBRT are an urgent priority.
Filed under: Management, Treatment | Tagged: complications, PBRT, proton beam, toxicity | 4 Comments »
The “New” Prostate Cancer InfoLink has learned that the results of the Phase III clinical trial of abiraterone acetate + prednisone in patients who progressed after treatment with docetaxel-based chemotherapy will be presented on October 11 at the annual meeting of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Filed under: Uncategorized | 2 Comments »
According to a thoroughly confusing media release from the Virginia Commonwealth University last week, “the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time.”
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: doxorubicin, sildenafil, Viagra | Leave a Comment »
Cabazitaxel (Jevtana®) has recently been approved in the USA for the treatment of men with castration-resistant prostate cancer who have progressive disease following treatment with standard first-line chemotherapy (docetaxel + prednisone).
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: cabazitaxel, Jevtana, side effects | 1 Comment »
OncoGenex Pharmaceuticals has recently announced the initiation of a randomized, controlled, investigator-sponsored Phase II clinical trial of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development | Tagged: OGX-427 | Leave a Comment »
We still have little to no idea why one man gets aggressive prostate cancer, another gets indolent prostate cancer, and a third is at no risk for prostate cancer at all.
Filed under: Drugs in development, Management, Prevention | Tagged: microRNA, risk, systems biology | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site